|Over a month ago|
BioDelivery Sciences price target lowered to $6.25 from $7 at Roth Capital » 14:2105/0605/06/21
Roth Capital analyst…
Roth Capital analyst Scott Henry lowered the firm's price target on BioDelivery Sciences to $6.25 from $7 and keeps a Buy rating on the shares following the company's Q1 results. The share price likely has overhang pending resolution of the Belbuca patent litigation, but BioDelivery's fundamentals are strong, Henry tells investors in a research note.
BioDelivery Sciences expects 2021 revenue $170M-$180M, consensus $179.53M » 08:3505/0605/06/21
The Company reiterates…
The Company reiterates its 2021 financial guidance, with full year 2021 total Company net sales of $170 - $180 million, including full year 2021 BELBUCA net sales of $155 - $165 million. Total operating expenses are expected to be in the range of $115 - $120 million, as the Company continues to invest to support the growth of its brands, and EBITDA is expected to be in the range of $40 - $50 million in 2021. The Company expects to continue delivering positive operating cash flow throughout 2021.
BioDelivery Sciences reports Q1 EPS 5c, consensus 7c » 08:3405/0605/06/21
Reports Q1 revenue $41M,…
Reports Q1 revenue $41M, consensus $41.34M. "We again delivered solid top and bottom-line growth in a challenging quarter against the backdrop of the pandemic and weather-related disruptions, resulting in 22% EBITDA margin and $11 million operating cash flow generation," stated Jeff Bailey, CEO of BDSI. "Our performance highlights the strength of our commercial team and the persistent market demand for our highly differentiated products. We expect continued success as the selling environment improves throughout the year, including increases of in-office patient visits and more face-to-face interactions with health care providers by our sales representatives."
|Over a quarter ago|
BioDelivery Sciences price target lowered to $5.50 from $7 at H.C. Wainwright » 06:1003/1103/11/21
H.C. Wainwright analyst…
H.C. Wainwright analyst Oren Livnat lowered the firm's price target on BioDelivery Sciences to $5.50 from $7 and keeps a Buy rating on the shares post the Q4 results. The analyst reduced estimates but views the 2021 guidance as likely conservative.
BioDelivery Sciences sees 2021 revenue $170M-$180M, consensus $190.23M » 08:0603/1003/10/21
The Company expects full…
The Company expects full year 2021 total net sales of $170 - $180 million, including full year 2021 BELBUCA net sales of $155 - $165 million. These estimates incorporate the expected impact in Q1 2021 from the winter storms in the South-Central region, which affected some of the Company's most productive territories. Total operating expenses are expected to be in the range of $115 - $120 million, as the Company continues to invest to support the growth of its brands, and EBITDA is expected to be in the range of $40 - $50 million in 2021. The Company expects to continue being operating cash flow positive throughout 2021.
BioDelivery Sciences reports Q4 EPS 10c, consensus 6c » 08:0503/1003/10/21
Reports Q4 revenue…
Reports Q4 revenue $42.2M, consensus $38.72M. "The impressive momentum and growth of our innovative products has persisted through the fourth quarter and full year 2020. Our high performing commercial team has been responding effectively to the evolving market conditions during the pandemic, and focused execution during the fourth quarter drove strong prescription trends for both BELBUCA and Symproic," stated Jeff Bailey, CEO of BDSI. "Our brands continued to capture market share in 2020 and the Company is poised for continued success as the selling environment improves in 2021."
Mexico Business Events to hold a virtual forum » 09:2502/1102/11/21
AXAS, ACTG, TALO, DQ, EMN, GLOP, GLOG, GEL, RNGR, NGS, LPX, REX, ESTE, LPI, BDSI, EXK, HRMY, DARE, JE, PLUG, REYN, RETO, STAG, AXU, BDTX, MANT
Mexico Mining Virtual…
Mexico Mining Virtual Forum will be held on February 10-11.Webcast Link
BioDelivery Sciences CFO Terry Coelho promoted to EVP » 08:1402/1102/11/21
BioDelivery Sciences International promoted its CFO Terry Coelho, to EVP and CFO. Terry joined BDSI as CFO in January 2019.
BioDelivery Sciences approves $25M stock repurchase plan » 08:2011/0511/05/20
Announced that its Board…
Announced that its Board of Directors authorized the repurchase of up to $25.0 million of the Company's shares of common stock. The Company plans to utilize existing cash on hand to fund the share repurchase program.
BioDelivery Sciences reports Q3 EPS 9c, consensus 5c » 08:2011/0511/05/20
Reports Q revenue $39.4M,…
Reports Q revenue $39.4M, consensus $39.35M. "Our commercial execution during the third quarter has been extremely impactful as evidenced by strong prescription trends for both BELBUCA and Symproic, which have continued in October," stated Jeff Bailey, CEO of BDSI. "I am proud to permanently join the talented BDSI team and very confident in our ability to execute on our vision to deliver innovative products to patients while maximizing shareholder value."